Skip to main content
. Author manuscript; available in PMC: 2012 Sep 19.
Published in final edited form as: Cancer Chemother Pharmacol. 2010 Oct 28;68(2):379–388. doi: 10.1007/s00280-010-1481-z

Table 3.

Response and progression-free survival

Stratum A: Normal
liver function
Stratum B: Abnormal
liver function
No of patients 23 10
Partial response
 No. 3 0
 Percent 13%
 (95% C.I.) (3%, 34%)
Progression-free survival
 Median (months) 3.7 3.6
 (95% Confidence
 intervals)
(2.7–5.8 months) (1.9–11.6 months)
Overall survival
 Median (months) 10. 3 3.6
 (95% Confidence
 intervals)
(5.9 months—upper
limit not reached)
(2.1–26.2 months)